Cipla launches rapid antigen detection test to diagnose COVID-19
The test will be marketed under the brand name CIPtest
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Cipla
Cipla settles patent litigation of Revlimid (lenalidomide) capsules with Celgene
Celgene has agreed to provide Cipla with a license to Celgene’s patents required to manufacture and sell certain volume-limited…
Cipla signs licensing pact with MultiG for COVID-19 rapid antibody test kit
'Covi-G' has been commercialised in 20+ countries, with sensitivity and specificity exceeding 92 per cent, informs company
Himachal Pradesh invites industry to sign MoU to set up units in proposed bulk drug park at Una
The State has identified 1,400 acres of land in Una for the bulk drug park and is promising competitive prices for land, power,…
Cipla launches ELIFast for COVID-19 antibody detection
The product will be marketed under the brand name ELIFast. Cipla’s expansive distribution network will help in ensuring the…
Cipla launches Nintib (Nintedanib) to treat Idiopathic Pulmonary Fibrosis
Cipla’s Nintib is priced at Rs 69 (100 mg) and Rs. 85 (150 mg) per capsule
Cipla gets US FDA approval for dimethyl fumarate DR capsules
It is indicated for the treatment of relapsing forms of multiple sclerosis
Stempeutics’ allogeneic cell therapy gets DCGI approval, Cipla to market and distribute…
Indicated for the treatment of CLI due to Buerger’s Disease and Atherosclerotic Peripheral Arterial Disease, it is the first…
Lee Pharma to launch favipiravir under brand name Faravir at Rs 27 per tablet
It has got DCGI nod to manufacture and market favipiravir APIs
Remdesivir shortage is India is easing: Cipla
The company has informed that it has started producing remdesivir at a plant in Goa in western India to ramp up production